67 related articles for article (PubMed ID: 15536457)
1. A variant 2677A allele of the MDR1 gene affects fexofenadine disposition.
Yi SY; Hong KS; Lim HS; Chung JY; Oh DS; Kim JR; Jung HR; Cho JY; Yu KS; Jang IJ; Shin SG
Clin Pharmacol Ther; 2004 Nov; 76(5):418-27. PubMed ID: 15536457
[TBL] [Abstract][Full Text] [Related]
2. MDR1 genotypes do not influence the absorption of a single oral dose of 600 mg valacyclovir in healthy Chinese Han ethnic males.
Zhang Y; Jiang XH; Hu YQ; Li ZR; Su L; Wang ZG; Ma G
Br J Clin Pharmacol; 2008 Aug; 66(2):247-54. PubMed ID: 18460034
[TBL] [Abstract][Full Text] [Related]
3. MDR1 Ala893 polymorphism is associated with inflammatory bowel disease.
Brant SR; Panhuysen CI; Nicolae D; Reddy DM; Bonen DK; Karaliukas R; Zhang L; Swanson E; Datta LW; Moran T; Ravenhill G; Duerr RH; Achkar JP; Karban AS; Cho JH
Am J Hum Genet; 2003 Dec; 73(6):1282-92. PubMed ID: 14610718
[TBL] [Abstract][Full Text] [Related]
4. Polymorphism of ORM1 is associated with the pharmacokinetics of telmisartan.
Chen WQ; Shu Y; Li Q; Xu LY; Roederer MW; Fan L; Wu LX; He FZ; Luo JQ; Tan ZR; He YJ; Zhou HH; Chen X; Zhang W
PLoS One; 2013; 8(8):e70341. PubMed ID: 23940561
[TBL] [Abstract][Full Text] [Related]
5. C3435T polymorphism in the
Jaramillo-Rangel G; Ortega-Martínez M; Cerda-Flores RM; Barrera-Saldaña HA
Int J Clin Exp Pathol; 2018; 11(2):904-909. PubMed ID: 31938182
[TBL] [Abstract][Full Text] [Related]
6. Association of
Jahromi AS; Erfanian S; Roustazadeh A
Heliyon; 2024 Mar; 10(6):e27304. PubMed ID: 38496859
[TBL] [Abstract][Full Text] [Related]
7. Intestinal P-gp activity is reduced in postmenopausal women under breast cancer therapy.
Ximenez JPB; de Andrade JM; Rocha A; Barbosa Coelho E; Suarez-Kurtz G; Lanchote VL
Clin Transl Sci; 2024 Jan; 17(1):e13713. PubMed ID: 38226443
[TBL] [Abstract][Full Text] [Related]
8. Effects of EPHX1 and CYP3A4 polymorphisms on carbamazepine metabolism in epileptic patients.
Caruso A; Bellia C; Pivetti A; Agnello L; Bazza F; Scazzone C; Bivona G; Lo Sasso B; Ciaccio M
Pharmgenomics Pers Med; 2014; 7():117-20. PubMed ID: 24817818
[TBL] [Abstract][Full Text] [Related]
9. Investigating the Potential Influence of
Gedvilaite G; Pileckaite E; Ramanauskas I; Kriauciuniene L; Balnyte R; Liutkeviciene R
J Pers Med; 2024 Apr; 14(4):. PubMed ID: 38673029
[TBL] [Abstract][Full Text] [Related]
10. Influence of ABCB1 C3435T polymorphism on the pharmacokinetics of lansoprazole and gastroesophageal symptoms in Japanese renal transplant recipients classified as CYP2C19 extensive metabolizers and treated with tacrolimus.
Miura M; Satoh S; Tada H; Saito M; Kagaya H; Inoue K; Sagae Y; Kanno S; Ishikawa M; Habuchi T; Suzuki T
Int J Clin Pharmacol Ther; 2006 Dec; 44(12):605-13. PubMed ID: 17190370
[TBL] [Abstract][Full Text] [Related]
11. A "silent" polymorphism in the MDR1 gene changes substrate specificity.
Kimchi-Sarfaty C; Oh JM; Kim IW; Sauna ZE; Calcagno AM; Ambudkar SV; Gottesman MM
Science; 2007 Jan; 315(5811):525-8. PubMed ID: 17185560
[TBL] [Abstract][Full Text] [Related]
12. Quantitative assessment of the relevance of organic-anion-transporting-polypeptide 1B1 and 2B1 polymorphisms in fexofenadine pharmacokinetic variants via pharmacometrics.
Jang JH; Jeong SH; Lee YB
J Pharm Anal; 2023 Jun; 13(6):660-672. PubMed ID: 37440913
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenomics of celiprolol - evidence for a role of P-glycoprotein and organic anion transporting polypeptide 1A2 in celiprolol pharmacokinetics.
Hirvensalo P; Tornio A; Tapaninen T; Paile-Hyvärinen M; Neuvonen M; Backman JT; Niemi M
Clin Transl Sci; 2022 Feb; 15(2):409-421. PubMed ID: 34585840
[TBL] [Abstract][Full Text] [Related]
14. ABCB1 in dermatology: roles in skin diseases and their treatment.
Weng HJ; Tsai TF
J Mol Med (Berl); 2021 Nov; 99(11):1527-1538. PubMed ID: 34370042
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics of amfepramone in healthy Mexican subjects reveals potential markers for tailoring pharmacotherapy of obesity: results of a randomised trial.
Gómez-Silva M; Piñeyro-Garza E; Vargas-Zapata R; Gamino-Peña ME; León-García A; de León MB; Llerena A; León-Cachón RBR
Sci Rep; 2019 Nov; 9(1):17833. PubMed ID: 31780765
[TBL] [Abstract][Full Text] [Related]
16. Effect of ABCB1 diplotype on tacrolimus disposition in renal recipients depends on CYP3A5 and CYP3A4 genotype.
Vanhove T; Annaert P; Lambrechts D; Kuypers DRJ
Pharmacogenomics J; 2017 Dec; 17(6):556-562. PubMed ID: 27378609
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of membrane transporters: a review of current approaches.
Sissung TM; Goey AK; Ley AM; Strope JD; Figg WD
Methods Mol Biol; 2014; 1175():91-120. PubMed ID: 25150868
[TBL] [Abstract][Full Text] [Related]
18. Digging up the human genome: current progress in deciphering adverse drug reactions.
Su SC; Chung WH; Hung SI
Biomed Res Int; 2014; 2014():824343. PubMed ID: 24734245
[TBL] [Abstract][Full Text] [Related]
19. MDR1 synonymous polymorphisms alter transporter specificity and protein stability in a stable epithelial monolayer.
Fung KL; Pan J; Ohnuma S; Lund PE; Pixley JN; Kimchi-Sarfaty C; Ambudkar SV; Gottesman MM
Cancer Res; 2014 Jan; 74(2):598-608. PubMed ID: 24305879
[TBL] [Abstract][Full Text] [Related]
20. Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients.
Han N; Yun HY; Hong JY; Kim IW; Ji E; Hong SH; Kim YS; Ha J; Shin WG; Oh JM
Eur J Clin Pharmacol; 2013 Jan; 69(1):53-63. PubMed ID: 22660440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
